Journal article
Tisagenlecleucel Immunogenicity in Relapsed/Refractory Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma
Abstract
Tisagenlecleucel is indicated for pediatric and young adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) and adult patients with r/r diffuse large B-cell lymphoma (DLBCL). The tisagenlecleucel chimeric antigen receptor (CAR) contains a murine single-chain variable fragment domain; we examined the effects of humoral and cellular immune responses to tisagenlecleucel on clinical outcomes using 2 validated …
Authors
Mueller KT; Grupp SA; Maude SL; Levine JE; Pulsipher MA; Boyer MW; August K; Myers GD; Tam CS; Jaeger U
Journal
Blood Advances, Vol. 5, No. 23, pp. 4980–4991
Publisher
American Society of Hematology
Publication Date
December 14, 2021
DOI
10.1182/bloodadvances.2020003844
ISSN
2473-9529